Related Experiment Video
Updated: Mar 17, 2026
06:19
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
4.0K
β-Ionone and its analogs as promising anticancer agents
1Student Research Committee, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
European Journal of Medicinal Chemistry
|July 31, 2016
Summary
Beta-ionone, found in fruits and vegetables, shows promise in cancer treatment. This review explores its potential for cancer prevention and chemotherapy, including new synthetic compounds.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Beta-ionone is a natural compound found in fruits and vegetables, structurally related to beta-carotenoids.
- Emerging research indicates beta-ionone possesses anti-proliferative, anti-metastatic, and apoptosis-inducing properties.
- Studies are investigating beta-ionone's effects on various cancer cell types and its mechanisms of action.
Purpose of the Study:
- To review the potential of beta-ionone and related compounds in cancer prevention.
- To explore the application of beta-ionone in chemotherapy strategies.
- To highlight the development of novel synthetic beta-ionone derivatives for cancer treatment.
Main Methods:
- Literature review of existing studies on beta-ionone and cancer.
- Analysis of in vitro and in vivo research on beta-ionone's anti-cancer effects.
- Examination of proposed mechanisms of action for beta-ionone in cancer cells.
Main Results:
- Beta-ionone demonstrates significant anti-proliferative and anti-metastatic activities against various cancer cell lines.
- Apoptosis induction has been observed as a key mechanism of beta-ionone's anti-cancer effects.
- Synthetic analogs of beta-ionone are being developed to enhance efficacy and overcome drug resistance.
Conclusions:
- Beta-ionone and its derivatives hold considerable potential as therapeutic agents for cancer prevention and chemotherapy.
- Targeted development of beta-ionone-based compounds may lead to novel combination therapies with reduced side effects.
- Further research is warranted to fully elucidate the clinical applications of beta-ionone in oncology.
Keywords:
Anti-proliferative activityAnticancer agentsApoptosisDrug designTerpenoid derivativesβ-IononeMore Related Videos
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
19.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.4K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
723
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
723
01:10Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K